Figure 3.

Epitope specificity of eight healthy control sera from the DASP 2010 workshop that showed assay-related differences in reactivity. The left panel shows the different GAD constructs used to assess epitope specificity with regions derived from GAD₆₅ shown in black, and those from GAD₆₇ shown in white. The right panel shows the reactivity of the control sera with these GAD constructs and the epitope reactivity ascribed to those sera based on the pattern of binding with the different constructs. Four sera (S8531, N53371, TS23727, and LQ21235) showed reactivity with GAD₆₅ N-terminal epitopes that was abolished by deletion of the first 95 amino acids (aa). Three control sera (N56575, N51532, and N59932) showed weak reactivity with the middle (MID) region of GAD₆₅ (amino acids 235–444), and this binding was not reduced by use of the N-terminally truncated labels.